Taken together, these results demonstrate that inhibition of DYRK1B efficiently represses GLI1 expression and reduces the malignant properties of GLI1 dependent cancer cells including pancreatic cancer cells with resistance to SMO inhibitors. Here, DYRK1B is linked to cancer.